Perspective  ||| S:0 E:12 ||| NNP
of  ||| S:12 E:15 ||| IN
vaccine  ||| S:15 E:23 ||| NN
manufacturers  ||| S:23 E:37 ||| NNS
on  ||| S:37 E:40 ||| IN
financing  ||| S:40 E:50 ||| VBG
pediatric  ||| S:50 E:60 ||| JJ
and  ||| S:60 E:64 ||| CC
adolescent  ||| S:64 E:75 ||| JJ
vaccines  ||| S:75 E:84 ||| NNS
in  ||| S:84 E:87 ||| IN
the  ||| S:87 E:91 ||| DT
United  ||| S:91 E:98 ||| NNP
States  ||| S:98 E:105 ||| NNPS
The  ||| S:105 E:109 ||| DT
goal  ||| S:109 E:114 ||| NN
was  ||| S:114 E:118 ||| VBD
to  ||| S:118 E:121 ||| TO
understand  ||| S:121 E:132 ||| VB
vaccine  ||| S:132 E:140 ||| NN
manufacturers ||| S:140 E:153 ||| NNS
'  ||| S:153 E:155 ||| POS
perspectives  ||| S:155 E:168 ||| NN
on  ||| S:168 E:171 ||| IN
vaccine  ||| S:171 E:179 ||| NN
financing  ||| S:179 E:189 ||| NN
as  ||| S:189 E:192 ||| IN
a  ||| S:192 E:194 ||| DT
barrier  ||| S:194 E:202 ||| NN
to  ||| S:202 E:205 ||| TO
immunization ||| S:205 E:217 ||| VB
.  ||| S:217 E:219 ||| .
Individual  ||| S:219 E:230 ||| JJ
telephone  ||| S:230 E:240 ||| NN
interviews  ||| S:240 E:251 ||| NNS
with  ||| S:251 E:256 ||| IN
representatives  ||| S:256 E:272 ||| NNS
of  ||| S:272 E:275 ||| IN
the  ||| S:275 E:279 ||| DT
6  ||| S:279 E:281 ||| CD
manufacturers  ||| S:281 E:295 ||| NNS
that  ||| S:295 E:300 ||| WDT
produce  ||| S:300 E:308 ||| VBP
routinely  ||| S:308 E:318 ||| RB
recommended  ||| S:318 E:330 ||| VBN
vaccines  ||| S:330 E:339 ||| NNS
for  ||| S:339 E:343 ||| IN
children  ||| S:343 E:352 ||| NNS
and  ||| S:352 E:356 ||| CC
adolescents  ||| S:356 E:368 ||| NNS
in  ||| S:368 E:371 ||| IN
the  ||| S:371 E:375 ||| DT
United  ||| S:375 E:382 ||| NNP
States  ||| S:382 E:389 ||| NNPS
were  ||| S:389 E:394 ||| VBD
conducted  ||| S:394 E:404 ||| VBN
in  ||| S:404 E:407 ||| IN
November  ||| S:407 E:416 ||| NNP
and  ||| S:416 E:420 ||| CC
December  ||| S:420 E:429 ||| NNP
2006 ||| S:429 E:433 ||| CD
.  ||| S:433 E:435 ||| .
Although  ||| S:435 E:444 ||| IN
manufacturers  ||| S:444 E:458 ||| NNS
acknowledged  ||| S:458 E:471 ||| VBD
that  ||| S:471 E:476 ||| IN
the  ||| S:476 E:480 ||| DT
price  ||| S:480 E:486 ||| NN
of  ||| S:486 E:489 ||| IN
newer  ||| S:489 E:495 ||| JJR
vaccines  ||| S:495 E:504 ||| NN
presents  ||| S:504 E:513 ||| VBZ
challenges  ||| S:513 E:524 ||| NNS
to  ||| S:524 E:527 ||| TO
optimal  ||| S:527 E:535 ||| VB
vaccine  ||| S:535 E:543 ||| NN
use ||| S:543 E:546 ||| NN
,  ||| S:546 E:548 ||| ,
they  ||| S:548 E:553 ||| PRP
asserted  ||| S:553 E:562 ||| VBD
that  ||| S:562 E:567 ||| IN
children  ||| S:567 E:576 ||| NNS
and  ||| S:576 E:580 ||| CC
adolescents  ||| S:580 E:592 ||| NNS
have  ||| S:592 E:597 ||| VBP
access  ||| S:597 E:604 ||| NN
to  ||| S:604 E:607 ||| TO
vaccinations  ||| S:607 E:620 ||| VB
through  ||| S:620 E:628 ||| IN
public  ||| S:628 E:635 ||| JJ
and  ||| S:635 E:639 ||| CC
private  ||| S:639 E:647 ||| JJ
insurance ||| S:647 E:656 ||| NN
.  ||| S:656 E:658 ||| .
Respondents  ||| S:658 E:670 ||| NNS
suggested  ||| S:670 E:680 ||| VBD
that  ||| S:680 E:685 ||| IN
the  ||| S:685 E:689 ||| DT
system  ||| S:689 E:696 ||| NN
could  ||| S:696 E:702 ||| MD
be  ||| S:702 E:705 ||| VB
improved  ||| S:705 E:714 ||| VBN
through  ||| S:714 E:722 ||| IN
adequate  ||| S:722 E:731 ||| JJ
funding  ||| S:731 E:739 ||| NN
of  ||| S:739 E:742 ||| IN
the  ||| S:742 E:746 ||| DT
public-sector  ||| S:746 E:760 ||| JJ
safety  ||| S:760 E:767 ||| NN
net ||| S:767 E:770 ||| NN
.  ||| S:770 E:772 ||| .
Respondents  ||| S:772 E:784 ||| NNS
stated  ||| S:784 E:791 ||| VBN
that  ||| S:791 E:796 ||| IN
providers  ||| S:796 E:806 ||| NNS
should  ||| S:806 E:813 ||| MD
receive  ||| S:813 E:821 ||| VB
timely  ||| S:821 E:828 ||| JJ
reimbursement  ||| S:828 E:842 ||| NN
for  ||| S:842 E:846 ||| IN
the  ||| S:846 E:850 ||| DT
full  ||| S:850 E:855 ||| JJ
costs  ||| S:855 E:861 ||| NNS
of  ||| S:861 E:864 ||| IN
vaccine  ||| S:864 E:872 ||| NN
purchase  ||| S:872 E:881 ||| NN
and  ||| S:881 E:885 ||| CC
administration ||| S:885 E:899 ||| NN
,  ||| S:899 E:901 ||| ,
and  ||| S:901 E:905 ||| CC
manufacturers  ||| S:905 E:919 ||| NNS
who  ||| S:919 E:923 ||| WP
sell  ||| S:923 E:928 ||| VBP
directly  ||| S:928 E:937 ||| RB
to  ||| S:937 E:940 ||| TO
health  ||| S:940 E:947 ||| NN
care  ||| S:947 E:952 ||| NN
providers  ||| S:952 E:962 ||| NNS
may  ||| S:962 E:966 ||| MD
provide  ||| S:966 E:974 ||| VB
flexible  ||| S:974 E:983 ||| JJ
payment  ||| S:983 E:991 ||| NN
terms  ||| S:991 E:997 ||| NNS
for  ||| S:997 E:1001 ||| IN
vaccine  ||| S:1001 E:1009 ||| NN
purchases ||| S:1009 E:1018 ||| NNS
.  ||| S:1018 E:1020 ||| .
Manufacturers  ||| S:1020 E:1034 ||| NNS
supported  ||| S:1034 E:1044 ||| VBD
targeted  ||| S:1044 E:1053 ||| VBN
expansion  ||| S:1053 E:1063 ||| NN
of  ||| S:1063 E:1066 ||| IN
the  ||| S:1066 E:1070 ||| DT
Vaccines  ||| S:1070 E:1079 ||| NNP
for  ||| S:1079 E:1083 ||| IN
Children  ||| S:1083 E:1092 ||| NNP
program  ||| S:1092 E:1100 ||| NN
to  ||| S:1100 E:1103 ||| TO
allow  ||| S:1103 E:1109 ||| VB
children  ||| S:1109 E:1118 ||| NNS
with  ||| S:1118 E:1123 ||| IN
incomplete  ||| S:1123 E:1134 ||| JJ
insurance  ||| S:1134 E:1144 ||| NN
coverage  ||| S:1144 E:1153 ||| NN
for  ||| S:1153 E:1157 ||| IN
vaccines  ||| S:1157 E:1166 ||| NNS
to  ||| S:1166 E:1169 ||| TO
receive  ||| S:1169 E:1177 ||| VB
vaccines  ||| S:1177 E:1186 ||| NNS
at  ||| S:1186 E:1189 ||| IN
health  ||| S:1189 E:1196 ||| NN
department  ||| S:1196 E:1207 ||| NN
clinics ||| S:1207 E:1214 ||| NNS
.  ||| S:1214 E:1216 ||| .
Manufacturers  ||| S:1216 E:1230 ||| NNS
perceived  ||| S:1230 E:1240 ||| VBN
delays  ||| S:1240 E:1247 ||| NNS
in  ||| S:1247 E:1250 ||| IN
publication  ||| S:1250 E:1262 ||| NN
of  ||| S:1262 E:1265 ||| IN
Advisory  ||| S:1265 E:1274 ||| NNP
Committee  ||| S:1274 E:1284 ||| NNP
on  ||| S:1284 E:1287 ||| IN
Immunization  ||| S:1287 E:1300 ||| NNP
Practices  ||| S:1300 E:1310 ||| NNPS
recommendations  ||| S:1310 E:1326 ||| NNS
as  ||| S:1326 E:1329 ||| IN
a  ||| S:1329 E:1331 ||| DT
potential  ||| S:1331 E:1341 ||| JJ
barrier  ||| S:1341 E:1349 ||| NN
to  ||| S:1349 E:1352 ||| TO
vaccine  ||| S:1352 E:1360 ||| NN
uptake ||| S:1360 E:1366 ||| NN
.  ||| S:1366 E:1368 ||| .
They  ||| S:1368 E:1373 ||| PRP
viewed  ||| S:1373 E:1380 ||| VBD
the  ||| S:1380 E:1384 ||| DT
perceived  ||| S:1384 E:1394 ||| JJ
lack  ||| S:1394 E:1399 ||| NN
of  ||| S:1399 E:1402 ||| IN
public  ||| S:1402 E:1409 ||| JJ
value  ||| S:1409 E:1415 ||| NN
for  ||| S:1415 E:1419 ||| IN
vaccines  ||| S:1419 E:1428 ||| NNS
as  ||| S:1428 E:1431 ||| IN
a  ||| S:1431 E:1433 ||| DT
potential  ||| S:1433 E:1443 ||| JJ
barrier  ||| S:1443 E:1451 ||| NN
to  ||| S:1451 E:1454 ||| TO
adequate  ||| S:1454 E:1463 ||| JJ
reimbursement  ||| S:1463 E:1477 ||| NN
and  ||| S:1477 E:1481 ||| CC
optimal  ||| S:1481 E:1489 ||| JJ
utilization ||| S:1489 E:1500 ||| NN
.  ||| S:1500 E:1502 ||| .
Respondents  ||| S:1502 E:1514 ||| NNS
also  ||| S:1514 E:1519 ||| RB
maintained  ||| S:1519 E:1530 ||| VBN
that  ||| S:1530 E:1535 ||| IN
their  ||| S:1535 E:1541 ||| PRP$
ability  ||| S:1541 E:1549 ||| NN
to  ||| S:1549 E:1552 ||| TO
negotiate  ||| S:1552 E:1562 ||| VB
vaccine  ||| S:1562 E:1570 ||| NN
prices  ||| S:1570 E:1577 ||| NNS
through  ||| S:1577 E:1585 ||| IN
the  ||| S:1585 E:1589 ||| DT
private  ||| S:1589 E:1597 ||| JJ
market  ||| S:1597 E:1604 ||| NN
is  ||| S:1604 E:1607 ||| VBZ
a  ||| S:1607 E:1609 ||| DT
crucial  ||| S:1609 E:1617 ||| JJ
priority ||| S:1617 E:1625 ||| NN
.  ||| S:1625 E:1627 ||| .
Manufacturers  ||| S:1627 E:1641 ||| NNS
assert  ||| S:1641 E:1648 ||| VBP
that  ||| S:1648 E:1653 ||| IN
children  ||| S:1653 E:1662 ||| NNS
and  ||| S:1662 E:1666 ||| CC
adolescents  ||| S:1666 E:1678 ||| NNS
have  ||| S:1678 E:1683 ||| VBP
access  ||| S:1683 E:1690 ||| NN
to  ||| S:1690 E:1693 ||| TO
immunizations  ||| S:1693 E:1707 ||| VB
through  ||| S:1707 E:1715 ||| IN
public  ||| S:1715 E:1722 ||| JJ
and  ||| S:1722 E:1726 ||| CC
private  ||| S:1726 E:1734 ||| JJ
insurance ||| S:1734 E:1743 ||| NN
.  ||| S:1743 E:1745 ||| .
Manufacturers  ||| S:1745 E:1759 ||| NNS
think  ||| S:1759 E:1765 ||| VBP
that  ||| S:1765 E:1770 ||| IN
they  ||| S:1770 E:1775 ||| PRP
have  ||| S:1775 E:1780 ||| VBP
mitigated  ||| S:1780 E:1790 ||| VBG
the  ||| S:1790 E:1794 ||| DT
challenge  ||| S:1794 E:1804 ||| NN
most  ||| S:1804 E:1809 ||| RBS
directly  ||| S:1809 E:1818 ||| RB
in  ||| S:1818 E:1821 ||| IN
their  ||| S:1821 E:1827 ||| PRP$
control ||| S:1827 E:1834 ||| NN
:  ||| S:1834 E:1836 ||| :
the  ||| S:1836 E:1840 ||| DT
large  ||| S:1840 E:1846 ||| JJ
financial  ||| S:1846 E:1856 ||| JJ
outlays  ||| S:1856 E:1864 ||| NNS
required  ||| S:1864 E:1873 ||| VBN
for  ||| S:1873 E:1877 ||| IN
up-front  ||| S:1877 E:1886 ||| JJ
vaccine  ||| S:1886 E:1894 ||| NN
purchases ||| S:1894 E:1903 ||| NNS
.  ||| S:1903 E:1905 ||| .
